CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 5%

CRISPR Therapeutics AG (NASDAQ:CRSP) shares dropped 5% on Thursday . The stock traded as low as $52.75 and last traded at $52.88. Approximately 443,840 shares were traded during mid-day trading, a decline of 75% from the average daily volume of 1,796,089 shares. The stock had previously closed at $55.65.

Analysts Set New Price Targets

CRSP has been the topic of several research reports. Royal Bank of Canada boosted their price target on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 22nd. Chardan Capital lifted their price objective on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. TheStreet raised shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a research note on Friday, February 23rd. Wells Fargo & Company boosted their target price on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the company an “equal weight” rating in a research note on Thursday, February 22nd. Finally, Mizuho boosted their target price on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $76.29.

CRISPR Therapeutics Stock Up 0.3 %

The firm has a fifty day moving average of $70.57 and a two-hundred day moving average of $63.81.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Wednesday, February 21st. The company reported $1.10 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.95. The firm had revenue of $201.20 million during the quarter, compared to the consensus estimate of $148.72 million. The business’s revenue for the quarter was up 3253.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.41) earnings per share. On average, research analysts anticipate that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.

Insider Activity

In other news, General Counsel James R. Kasinger sold 1,913 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the transaction, the general counsel now owns 57,371 shares in the company, valued at $4,570,747.57. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 2,801 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $78.26, for a total value of $219,206.26. Following the sale, the general counsel now owns 60,070 shares in the company, valued at approximately $4,701,078.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, General Counsel James R. Kasinger sold 1,913 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total value of $152,408.71. Following the completion of the sale, the general counsel now owns 57,371 shares in the company, valued at approximately $4,570,747.57. The disclosure for this sale can be found here. Insiders have sold a total of 133,992 shares of company stock worth $9,157,835 over the last 90 days. 4.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Hedge funds have recently bought and sold shares of the stock. Blue Trust Inc. purchased a new position in shares of CRISPR Therapeutics during the 4th quarter valued at approximately $32,000. Bourgeon Capital Management LLC raised its stake in CRISPR Therapeutics by 1,000.0% in the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock valued at $34,000 after purchasing an additional 500 shares during the last quarter. CWM LLC raised its stake in CRISPR Therapeutics by 80.7% in the 3rd quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after purchasing an additional 260 shares during the last quarter. NBC Securities Inc. raised its stake in CRISPR Therapeutics by 257.6% in the 1st quarter. NBC Securities Inc. now owns 608 shares of the company’s stock valued at $41,000 after purchasing an additional 438 shares during the last quarter. Finally, Principal Securities Inc. acquired a new position in CRISPR Therapeutics in the 4th quarter valued at $41,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.